Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study
Clinical trial NCT07550452 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07550452
- Sponsor
- Peking University People's Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-31
- Primary completion
- 2027-06-30
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.